Details of the Drug

General Information of Drug (ID: DM458UM)

Drug Name
Captopril
Synonyms
Acediur; Aceplus; Acepress; Acepril; Alopresin; Apopril; Asisten; Capoten; Captolane; Captoprilum; Captopryl; Captoril; Captril; Cesplon; Dilabar; Garranil; Hipertil; Hypertil; Isopresol; Lopirin; Lopril; MCO; Tenosbon; Tensiomin; Tensobon; Tensoprel; Lopirin [Switzerland]; C 4042; SA 333; SQ 14225; X8Z; Apopril (TN); Capoten (TN); Captoprilum [INN-Latin]; Garranil (discontinued); L-Captopril; SQ 14,225; SQ-14225; SQ-14534; SQ-14,225; SQ-14,534; Captopril (JP15/USP/INN); Captopril [USAN:INN:BAN:JAN]; D-3-Mercapto-2-methylpropionylproline; D-2-Methyl-3-mercaptopropanoyl-L-proline; D-3-Mercapto-2-methylpropanoyl-L-proline; [2S]-1-[3-Mercapto-2-methylpropionyl]-L-proline; N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline;(2S)-1-(3-Mercapto-2-methylpropionyl)-L-proline; (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid; (S)-1-(3-Mercapto-2-methyl-1-oxo-propyl)-L-proline; (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; 1-((2S)-3-Mercapto-2-methylpropionyl)-L-proline; 1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; 1-(D-3-Mercapto-2-methyl-1-oxopropyl)-L-proline (S,S); 1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline; 3-Mercapto-2-methylpropionyl-proline
Indication
Disease Entry ICD 11 Status REF
Chronic heart failure BD1Z Approved [1]
Diabetic kidney disease GB61.Z Approved [1]
Hypertension BA00-BA04 Approved [2]
Malignant essential hypertension BA00 Approved [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [3]
Therapeutic Class
Antihypertensive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 217.29
Logarithm of the Partition Coefficient (xlogp) 0.3
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Bioavailability
69% of drug becomes completely available to its intended biological destination(s) [5]
Clearance
The drug present in the plasma can be removed from the body at the rate of 12 mL/min/kg [6]
Elimination
38% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 2 hours [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 19.7235 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.73% [6]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.75 L/kg [6]
Water Solubility
The ability of drug to dissolve in water is measured as 160 mg/mL [4]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Adverse drug reaction Not Available SLC2A1 OTA675TJ [8]
Adverse drug reaction Not Available SLC2A2 OTBL2W7R [8]
Blood pressure decreased Not Available KNG1 OT4X9LDE [8]
Blood pressure decreased Not Available KLK10 OTD573EL [8]
Cough Not Available BDKRB2 OTOA9D3W [8]
Leukopenia Not Available GUSB OT9N1DK3 [8]
Leukopenia Not Available LYZ OTD7H0G6 [8]
⏷ Show the Full List of 7 ADR Information of This Drug
Chemical Identifiers
Formula
C9H15NO3S
IUPAC Name
(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
Canonical SMILES
C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O
InChI
InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1
InChIKey
FAKRSMQSSFJEIM-RQJHMYQMSA-N
Cross-matching ID
PubChem CID
44093
ChEBI ID
CHEBI:3380
CAS Number
62571-86-2
DrugBank ID
DB01197
TTD ID
D0I0EG
VARIDT ID
DR00628
INTEDE ID
DR0269
ACDINA ID
D00096
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiotensin-converting enzyme (ACE) TTL69WB ACE_HUMAN Inhibitor [9]
HUMAN angiotensin-converting enzyme (ACE) TTGFNPD ACE_HUMAN Inhibitor [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [12]
Thiopurine methyltransferase (TPMT) DEFQ8VO TPMT_HUMAN Substrate [13]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Drug Response [14]
B2 bradykinin receptor (BDKRB2) OTOA9D3W BKRB2_HUMAN Drug Response [8]
Beta-glucuronidase (GUSB) OT9N1DK3 BGLR_HUMAN Drug Response [8]
Kallikrein-10 (KLK10) OTD573EL KLK10_HUMAN Drug Response [8]
Kininogen-1 (KNG1) OT4X9LDE KNG1_HUMAN Drug Response [8]
Lysozyme C (LYZ) OTD7H0G6 LYSC_HUMAN Drug Response [8]
Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1) OTA675TJ GTR1_HUMAN Drug Response [8]
Solute carrier family 2, facilitated glucose transporter member 2 (SLC2A2) OTBL2W7R GTR2_HUMAN Drug Response [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Chronic heart failure
ICD Disease Classification BD1Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Angiotensin-converting enzyme (ACE) DTT SLC33A1 2.62E-01 -0.01 -0.06
Peptide transporter 1 (SLC15A1) DTP PEPT1 6.91E-01 8.30E-03 7.24E-02
Thiopurine methyltransferase (TPMT) DME TPMT 7.77E-01 -1.39E-01 -4.43E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 5.64E-01 2.36E-02 1.75E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Captopril
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Aliskiren DM1BV7W Major Increased risk of hyperkalemia by the combination of Captopril and Aliskiren. Hypertension [BA00-BA04] [15]
TAK-491 DMCF6SX Major Increased risk of hyperkalemia by the combination of Captopril and TAK-491. Hypertension [BA00-BA04] [16]
Coadministration of a Drug Treating the Disease Different from Captopril (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Captopril and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [17]
Sodium bicarbonate DMMU6BJ Minor Decreased absorption of Captopril due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [18]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Captopril and Insulin-glulisine. Acute diabete complication [5A2Y] [19]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Captopril and Insulin-aspart. Acute diabete complication [5A2Y] [20]
Gilteritinib DMTI0ZO Moderate Decreased clearance of Captopril due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [21]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Captopril and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [22]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Captopril and Cariprazine. Bipolar disorder [6A60] [23]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Captopril and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [24]
Talazoparib DM1KS78 Moderate Decreased clearance of Captopril due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [25]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Captopril and Drospirenone. Contraceptive management [QA21] [26]
Ardeparin DMYRX8B Moderate Increased risk of hyperkalemia by the combination of Captopril and Ardeparin. Coronary thrombosis [BA43] [16]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Captopril and Isocarboxazid. Depression [6A70-6A7Z] [27]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Captopril and OPC-34712. Depression [6A70-6A7Z] [23]
SODIUM CITRATE DMHPD2Y Minor Decreased absorption of Captopril due to altered gastric pH caused by SODIUM CITRATE. Discovery agent [N.A.] [18]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Captopril and Cannabidiol. Epileptic encephalopathy [8A62] [21]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Captopril and Brentuximab vedotin. Hodgkin lymphoma [2B30] [28]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Captopril and Mipomersen. Hyper-lipoproteinaemia [5C80] [29]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Captopril and BMS-201038. Hyper-lipoproteinaemia [5C80] [30]
Tolvaptan DMIWFRL Moderate Increased risk of hyperkalemia by the combination of Captopril and Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [31]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Captopril and ITI-007. Insomnia [7A00-7A0Z] [23]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Captopril and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [32]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Captopril and Idelalisib. Mature B-cell leukaemia [2A82] [33]
GDC-0199 DMH0QKA Major Decreased clearance of Captopril due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [17]
Arry-162 DM1P6FR Moderate Decreased clearance of Captopril due to the transporter inhibition by Arry-162. Melanoma [2C30] [17]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Captopril and Ozanimod. Multiple sclerosis [8A40] [27]
Polythiazide DMCH80F Moderate Additive hypotensive effects by the combination of Captopril and Polythiazide. Oedema [MG29] [34]
S-297995 DM26IH8 Moderate Decreased clearance of Captopril due to the transporter inhibition by S-297995. Opioid use disorder [6C43] [21]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Captopril and Safinamide. Parkinsonism [8A00] [27]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Captopril and Rasagiline. Parkinsonism [8A00] [27]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Captopril and Silodosin. Prostate hyperplasia [GA90] [35]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Captopril and Levomepromazine. Psychotic disorder [6A20-6A25] [23]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Captopril and Quetiapine. Schizophrenia [6A20] [23]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Captopril and Aripiprazole. Schizophrenia [6A20] [23]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Captopril and Iloperidone. Schizophrenia [6A20] [23]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Captopril and Paliperidone. Schizophrenia [6A20] [23]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Captopril and Molindone. Schizophrenia [6A20] [23]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Captopril and Thiothixene. Schizophrenia [6A20] [23]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Captopril and Asenapine. Schizophrenia [6A20] [23]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Captopril and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [21]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Captopril and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [19]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Captopril and Insulin degludec. Type-1/2 diabete [5A10-5A11] [19]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Captopril and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [36]
Betrixaban DM2C4RF Moderate Decreased clearance of Captopril due to the transporter inhibition by Betrixaban. Venous thromboembolism [BD72] [37]
⏷ Show the Full List of 43 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Palmitic acid E00037 985 Emulsifying agent; Penetration agent; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Captopril 100 mg tablet 100 mg Oral Tablet Oral
Captopril 12.5 mg tablet 12.5 mg Oral Tablet Oral
Captopril 25 mg tablet 25 mg Oral Tablet Oral
Captopril 50 mg tablet 50 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Captopril FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5158).
3 ClinicalTrials.gov (NCT04345406) Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19. U.S. National Institutes of Health.
4 BDDCS applied to over 900 drugs
5 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
9 Using ACE inhibitors appropriately. Am Fam Physician. 2002 Aug 1;66(3):461-8.
10 Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. Curr Cardiol Rep. 2020 Apr 14;22(5):31.
11 Membrane transporters in drug development. Nat Rev Drug Discov. 2010 Mar;9(3):215-36.
12 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
13 S-methylation of captopril. Demonstration of captopril thiol methyltransferase activity in human erythrocytes and enzyme distribution in rat tissues. Biochem Pharmacol. 1983 May 15;32(10):1557-62.
14 Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women. Clin Pharmacol Ther. 2007 Aug;82(2):187-96. doi: 10.1038/sj.clpt.6100214. Epub 2007 May 2.
15 Health Canada "Potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes treated with aliskiren (RASILEZ) or aliskiren/hydrochlorothiazide (RASILEZ HCT)." .
16 Product Information. Diovan (valsartan). Novartis Pharmaceuticals, East Hanover, NJ.
17 Cerner Multum, Inc. "Australian Product Information.".
18 Mantyla R, Mannisto PT, Vuorela A, Sundberg S, Ottoila P "Impairment of captopril bioavailability by concomitant food and antacid intake." Int J Clin Pharmacol Ther Toxicol 22 (1984): 626-9. [PMID: 6389377]
19 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
20 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
21 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
22 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
23 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
24 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
25 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
26 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
27 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
28 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
29 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
30 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
31 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
32 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
33 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
34 Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2. [PMID: 6391404]
35 Baba T, Tomiyama T, Takebe K "Enhancement by an ACE inhibitor of first-dose hypotension caused by an alpha-blocker." N Engl J Med 322 (1990): 1237. [PMID: 1970122]
36 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
37 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.